Bariatrics Editorial
Bariatrics News & Physician Commentary
Apollo Endosurgery, Inc. Announces FDA Approval of the ORBERA™ Intragastric Balloon, a Non-Surgical Solution to Assist Patients in Weight Loss
Austin, TX (August 6, 2015) — Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced that the U.S. Food and Drug Administration (FDA) has approved the ORBERA™ Intragastric Balloon to assist adult patients suffering from obesity – with a body mass index (BMI) of 30 to […]
Apollo Endosurgery, Inc. Announces the Presentation of ORBERA™ Intragastric Balloon US Pivotal Trial Results at Digestive Disease Week® 2015 Conference (DDW)
Austin, TX (May 18, 2015) – Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced the presentation of results from the ORBERA™ Pivotal Trial at this year’s Digestive Disease Week (DDW) conference. The study showed that ORBERA™ Intragastric Balloon users lost significantly more weight than the […]
Apollo Endosurgery Announces Stefanie Cavanaugh as Chief Financial Officer
AUSTIN, TX (March 17, 2015) – Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced that it has appointed Stefanie Cavanaugh as Chief Financial Officer. Cavanaugh brings to Apollo Endosurgery more than 30 years of financial management experience. She will be reporting to Apollo Endosurgery’s Chief […]
Apollo Endosurgery Completes $50 Million Financing
AUSTIN, TX (February 27, 2015) – Apollo Endosurgery, Inc. (“Apollo”), a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced it has closed a $50 million secured term loan provided by Athyrium Capital Management through its Athyrium Opportunities Fund II (together, “Athyrium”). The secured term loan was used to repay […]